The impact of 10-valent and 13-valent pneumococcal conjugate vaccines on serotype 19A invasive pneumococcal disease

References

• Oosterhuis-Kafeja F, Beutels P, Van Damme P. Immunogenicity, efficacy, safety and effectiveness of pneumococcal conjugate vaccines (1998-2006). Vaccine 2007;25:2194-212
   PubMed Web of Science ®Google Scholar
• Conklin L, Loo JD, Kirk J, et al. Systematic review of the effect of pneumococcal conjugate vaccine dosing schedules on vaccine-type invasive pneumococcal disease among young children. Pediatr Infect Dis J 2014;33(Suppl 2):S109-118
   PubMed Web of Science ®Google Scholar
• Scott P, Rutjes AW, Bermetz L, et al. Comparing pneumococcal conjugate vaccine schedules based on 3 and 2 primary doses: systematic review and meta-analysis. Vaccine 2011;29:9711-21
   PubMed Web of Science ®Google Scholar
• Centers for Disease Control and Prevention. Direct and indirect effects of routine vaccination of children with 7-valent pneumococcal conjugate vaccine on incidence of invasive pneumococcal disease–United States, 1998-2003. MMWR Morb Mortal Wkly Rep 2005;54:893-7
   PubMedGoogle Scholar
• Navarro Torné A, Dias JG, Quinten C, et al. European enhanced surveillance of invasive pneumococcal disease in 2010: data from 26 European countries in the post-heptavalent conjugate vaccine era. Vaccine 2014;32:3644-50
   PubMed Web of Science ®Google Scholar
• Moore MR, Gertz REJr, Woodbury RL, et al. Population snapshot of emergent Streptococcus pneumoniae serotype 19A in the United States, 2005. J Infect Dis 2008;197:1016-27
   PubMed Web of Science ®Google Scholar
• Reinert RR, Jacobs MR, Kaplan SL. Pneumococcal disease caused by serotype 19A: review of the literature and implications for future development. Vaccine 2010;28:4249-59
   PubMed Web of Science ®Google Scholar
• Centers for Disease Control and Prevention. Licensure of a 13-valent pneumococcal conjugate vaccine (PCV13) and recommendations for use among children - Advisory Committee on Immunization Practices (ACIP), 2010. MMWR Morb Mortal Wkly Rep 2010;59:258-61
   PubMedGoogle Scholar
• Synflorix, pneumococcal polysaccharide conjugate vaccine (adsorbed): summary of product characteristics [Internet]. European Medicines Agency, London, 2014; p. c1995. Available from: www.ema.europa.eu/docs/en_GB/docu ment_library/EPAR_-_Product_Information/human/000973/WC500054346.pdf [ [Last accessed 12 May 2015]
   Google Scholar
• Lee H, Nahm MH, Burton R, Kim KH. Immune response in infants of the heptavalent pneumococcal conjugate vaccine against vaccine-related serotypes 6A and 19A. Clin Vaccine Immunol 2009;16:376-81
   PubMed Web of Science ®Google Scholar
• Kieninger DM, Kueper K, Steul K, et al. Safety, tolerability, and immunologic noninferiority of a 13-valent pneumococcal conjugate vaccine compared to a 7-valent pneumococcal conjugate vaccine given with routine pediatric vaccinations in Germany. Vaccine 2010;28:4192-203
   PubMed Web of Science ®Google Scholar
• Whitney CG, Pilishvili T, Farley MM, et al. Effectiveness of seven-valent pneumococcal conjugate vaccine against invasive pneumococcal disease: a matched case-control study. Lancet 2006;368:1495-502
   PubMed Web of Science ®Google Scholar
• Hausdorff WP, Hoet B, Schueman L. Do pneumococcal conjugate vaccines provide any cross-protection against serotype 19A? BMC Pediatr 2010;10:4
   PubMed Web of Science ®Google Scholar
• Rodgers GL, Esposito S, Principi N, et al. Immune response to 13-valent pneumococcal conjugate vaccine with a reduced dosing schedule. Vaccine 2013;31:4765-74
   PubMed Web of Science ®Google Scholar
• Cohen R, Levy C, Bingen E, et al. Impact of 13-valent pneumococcal conjugate vaccine on pneumococcal nasopharyngeal carriage in children with acute otitis media. Pediatr Infect Dis J 2012;31:297-301
   PubMed Web of Science ®Google Scholar
• Dagan R, Patterson S, Juergens C, et al. Comparative immunogenicity and efficacy of 13-valent and 7-valent pneumococcal conjugate vaccines in reducing nasopharyngeal colonization: a randomized double-blind trial. Clin Infect Dis 2013;57:952-62
   PubMed Web of Science ®Google Scholar
• Poolman J, Frasch C, Nurkka A, et al. Impact of the conjugation method on the immunogenicity of Streptococcus pneumoniae serotype 19F polysaccharide in conjugate vaccines. Clin Vaccine Immunol 2011;18:327-36
   PubMed Web of Science ®Google Scholar
• Vesikari T, Wysocki J, Chevallier B, et al. Immunogenicity of the 10-valent pneumococcal non-typeable Haemophilus influenzae protein D conjugate vaccine (PHiD-CV) compared to the licensed 7vCRM vaccine Pediatr. Infect Dis J 2009;28(4 Suppl):S66-76
   Web of Science ®Google Scholar
• Wysocki J, Tejedor JC, Grunert D, et al. Immunogenicity of the 10-valent pneumococcal non-typeable Haemophilus influenzae protein D conjugate vaccine (PHiD-CV) when coadministered with different Neisseria meningitidis serogroup C conjugate vaccines. Pediatr Infect Dis J 2009;28(4 Suppl):S77-88
   PubMed Web of Science ®Google Scholar
• Bermal N, Szenborn L, Chrobot A, et al. The 10-valent pneumococcal non-typeable Haemophilus influenzae protein D conjugate vaccine (PHiD-CV) coadministered with DTPw-HBV/Hib and poliovirus vaccines: assessment of immunogenicity. Pediatr Infect Dis J 2009;28(4 Suppl):S89-96
   PubMed Web of Science ®Google Scholar
• Bermal N, Szenborn L, Edison A, et al. Safety and immunogenicity of a booster dose of the 10-valent pneumococcal nontypeable Haemophilus influenzae protein D conjugate vaccine coadministered with DTPw-HBV/Hib and poliovirus vaccines. Pediatr Infect Dis J 2011;30:69-72
   PubMed Web of Science ®Google Scholar
• van den Bergh MR, Spijkerman J, François N, et al. Immunogenicity, safety, and reactogenicity of the 10-valent pneumococcal nontypeable Haemophilus influenzae protein D conjugate vaccine and DTPa-IPV-Hib when coadministered as a 3-dose primary vaccination schedule in The Netherlands: a randomized controlled trial. Pediatr Infect Dis J 2011;30:e170-8
   PubMed Web of Science ®Google Scholar
• Kim CH, Kim JS, Cha SH, et al. Response to primary and booster vaccination with 10-valent pneumococcal nontypeable Haemophilus influenzae protein D conjugate vaccine in Korean infants. Pediatr Infect Dis J 2011;30:e235-43
   PubMed Web of Science ®Google Scholar
• van den Bergh MR, Spijkerman J, Swinnen KM, et al. Effects of the 10-valent pneumococcal nontypeable Haemophilus influenzae protein D-conjugate vaccine on nasopharyngeal bacterial colonization in young children: a randomized controlled trial. Clin Infect Dis 2013;56:e30-9
   PubMed Web of Science ®Google Scholar
• Moore MR, Link-Gelles R, Schaffner W, et al. Effect of use of 13-valent pneumococcal conjugate vaccine in children on invasive pneumococcal disease in children and adults in the USA: analysis of multisite, population-based surveillance. Lancet Infect Dis 2015;15:301-9
   PubMed Web of Science ®Google Scholar
• Waight PA, Andrews NJ, Ladhani SN, et al. Effect of the 13-valent pneumococcal conjugate vaccine on invasive pneumococcal disease in England and Wales 4 years after its introduction: an observational cohort study. Lancet Infect Dis 2015;15:535-43
   PubMed Web of Science ®Google Scholar
• Lepoutre A, Varon E, Georges S, et al. Impact of the pneumococcal conjugate vaccines on invasive pneumococcal disease in France, 2001-2012. Vaccine 2015;33:359-66
   PubMed Web of Science ®Google Scholar
• Harboe ZB, Dalby T, Weinberger DM, et al. Impact of 13-valent pneumococcal conjugate vaccination in invasive pneumococcal disease incidence and mortality. Clin Infect Dis 2014;59:1066-73
   PubMed Web of Science ®Google Scholar
• Steens A, Bergsaker MA, Aaberge IS, et al. Prompt effect of replacing the 7-valent pneumococcal conjugate vaccine with the 13-valent vaccine on the epidemiology of invasive pneumococcal disease in Norway. Vaccine 2013;31:6232-8
   PubMed Web of Science ®Google Scholar
• Picazo J, Ruiz-Contreras J, Casado-Flores J, et al. Expansion of serotype coverage in the universal pediatric vaccination calendar: short-term effects on age- and serotype-dependent incidence of invasive pneumococcal clinical presentations in Madrid. Spain. Clin Vaccine Immunol 2013;20:1524-30
   PubMed Web of Science ®Google Scholar
• Palmu AA, Jokinen J, Borys D, et al. Effectiveness of the ten-valent pneumococcal Haemophilus influenzae protein D conjugate vaccine (PHiD-CV10) against invasive pneumococcal disease: a cluster randomised trial. Lancet 2013;381:214-22
   PubMed Web of Science ®Google Scholar
• Jokinen J, Rinta-Kokko H, Siira L, et al. Impact of ten-valent pneumococcal conjugate vaccination on invasive pneumococcal disease in Finnish children-a population-based study. PLoS One 2015;10:e0120290
   PubMed Web of Science ®Google Scholar
• Domingues CM, Verani JR, Montenegro Renoiner EI, et al. Effectiveness of ten-valent pneumococcal conjugate vaccine against invasive pneumococcal disease in Brazil: a matched case-control study. Lancet Respir Med 2014;2:464-71
   PubMed Web of Science ®Google Scholar
• Deceuninck G, De Serres G, Boulianne N, et al. Effectiveness of three pneumococcal conjugate vaccines to prevent invasive pneumococcal disease in Quebec. Canada. Vaccine 2015. [Epub ahead of print]
   Google Scholar
• Organizatión Panamericana per la Salud. Informe Regional de SIREVA II, 2012. Available from: www.paho.org/hq/index.php?option=com_content&view=category&layout=blog&id=3609&Itemid=3953 [Last accessed 11 May 2015]
   Google Scholar
• Institute of Environmental Science and Research Ltd (ESR). Invasive Pneumococcal Disease. Quarterly Report April−June 2014. Available from: https://surv.esr.cri.nz/PDF_surveillance/IPD/2014/2014Q2_IPDReport.pdf [Last accessed 11 May 2015]
   Google Scholar
• Andrews NJ, Waight PA, Burbidge P, et al. Serotype-specific effectiveness and correlates of protection for the 13-valent pneumococcal conjugate vaccine: a postlicensure indirect cohort study. Lancet Infect Dis 2014;14:839-46
   PubMed Web of Science ®Google Scholar
• Vanderkooi OG, Scheifele DW, Girgenti D, et al. Safety and immunogenicity of a 13-valent pneumococcal conjugate vaccine in healthy infants and toddlers given with routine pediatric vaccinations in Canada. Pediatr Infect Dis J 2012;31:72-7
   PubMed Web of Science ®Google Scholar
• Plosker GL. 13-valent pneumococcal conjugate vaccine: a review of its use in infants, children, and adolescents. Paediatr Drugs 2013;15:403-23
   PubMed Web of Science ®Google Scholar
• Jefferies JM, Macdonald E, Faust SN, Clarke SC. 13-valent pneumococcal conjugate vaccine (PCV13). Hum Vaccin 2011;7:1012-18
   PubMed Web of Science ®Google Scholar
• Simell B, Auranen K, Käyhty H, Pneumococcal Carriage Group. The fundamental link between pneumococcal carriage and disease. Expert Rev Vaccines 2012;11:841-55
   PubMed Web of Science ®Google Scholar
• Tromp KM, Campbell MW, Vazquez A. Recent developments and future directions of pneumococcal vaccine recommendations. Clin Ther 2015. [Epub ahead of print]
   PubMed Web of Science ®Google Scholar